Argenica Therapeutics Ltd
ASX:AGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Mahamaya Steel Industries Ltd
NSE:MAHASTEEL
|
IN |
|
Osirium Technologies PLC
LSE:OSI
|
UK |
Argenica Therapeutics Ltd
Operating Expenses
Argenica Therapeutics Ltd
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Argenica Therapeutics Ltd
ASX:AGN
|
Operating Expenses
-AU$10.7m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-95%
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Operating Expenses
-AU$27.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Operating Expenses
-AU$324.1m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Operating Expenses
-AU$42.6m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-9%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Operating Expenses
-AU$69.1m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-48%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Operating Expenses
-AU$8.1m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Argenica Therapeutics Ltd
Glance View
Argenica Therapeutics Ltd. provides neuroprotective treatment. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2021-06-11. Argenica’s lead candidate, ARG-007, aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury. Argenica has accumulated a comprehensive body of published pre-clinical studies demonstrating efficacy of ARG-007 in multiple models of stroke and other central nervous system injury models, including stroke, traumatic brain injury and perinatal hypoxia ischaemia.
See Also
What is Argenica Therapeutics Ltd's Operating Expenses?
Operating Expenses
-10.7m
AUD
Based on the financial report for Jun 30, 2025, Argenica Therapeutics Ltd's Operating Expenses amounts to -10.7m AUD.
What is Argenica Therapeutics Ltd's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-95%
Over the last year, the Operating Expenses growth was -30%. The average annual Operating Expenses growth rates for Argenica Therapeutics Ltd have been -36% over the past three years , -95% over the past five years .
